Type of security: Stock
Sector: Health Care
Industry: Biotechnology: Biological Products (No Diagnostic Substances)
The data is delayed by 15 minutes.
Description: bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing gene therapies for severe genetic and orphan diseases. The company?s advanced product candidate is Lenti-D, which is in phase II/III studies for the treatment of childhood cerebral adrenoleukodystrophy, a rare, hereditary neurological disorder affecting young boys; and LentiGlobin that is in phase I/II studies for the treatment of beta-thalassemia major and severe sickle cell disease in France, as well as a second phase I/II studies with LentiGlobin for the treatment of beta-thalassemia major in the United States. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||-7.22||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||0.14%||Sales Growth - Q/Q||-0.66%||P/E||-15.06|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-11.78%||ROE||-13.25%||ROI|
|Current Ratio||8.11||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.09|
|Gross Margin||Operating Margin||-294.47%||Net Profit Margin||-247.3%||Dividend Payout Ratio|
|Cash From Financing Activities||2.46 M||Cash From Investing Activities||-192.98 M||Cash From Operating Activities||-24.16 M||Gross Profit|
|Net Profit||-24.79 M||Operating Profit||-24.93 M||Total Assets||533.82 M||Total Current Assets||340.84 M|
|Total Current Liabilities||42.01 M||Total Debt||Total Liabilities||59.32 M||Total Revenue||6.34 M|
|High 52 week||197||Low 52 week||91.25||Last close||141||Last change||-1.4%|
|RSI||28.94||Average true range||5.96||Beta||1.77||Volume||513.89 K|
|Simple moving average 20 days||-5.97%||Simple moving average 50 days||-5.32%||Simple moving average 200 days||2.08%|
|Performance Week||4.04%||Performance Month||-7.86%||Performance Quart||11.67%||Performance Half||26.38%|
|Performance Year||-18.61%||Performance Year-to-date||42.14%||Volatility daily||2.85%||Volatility weekly||6.36%|
|Volatility monthly||13.04%||Volatility yearly||45.17%||Relative Volume||135.56%||Average Volume||495.42 K|
|New High||New Low|
2019-05-25 12:30:42 | Marshall Wace’s Latest Moves
2019-05-19 07:00:00 | Top 5 New Drug Launches of 2019 -- and the Biotech Stocks That Could Win Big
2019-05-16 09:12:00 | bluebird bio to Present New Data from Clinical Studies of LentiGlobin™ Gene Therapy for Transfusion-Dependent ?-thalassemia TDT and LentiGlobin Gene Therapy for Sickle Cell Disease SCD at the 24th EHA Congress
2019-05-15 14:10:36 | Bluebird Bio's Near-Term Product Launches Pose Risks, Wedbush Says In Downgrade
2019-05-15 10:49:00 | Bluebird Bio’s Pricing Plan Worries One Biotech Analyst. Here’s Why.
2019-05-08 08:12:00 | bluebird bio Flies Forward
2019-05-07 08:04:37 | See what the IHS Markit Score report has to say about bluebird bio Inc.
2019-05-06 11:50:03 | bluebird's BLUE Loss Wider Than Expected, Revenues Down Y/Y
2019-05-03 08:00:00 | bluebird bio Announces Investor Events in May
2019-05-02 18:45:10 | Bluebird Bio BLUE Reports Q1 Loss, Tops Revenue Estimates
2019-05-02 17:40:44 | Bluebird: 1Q Earnings Snapshot
2019-05-01 17:01:00 | Celgene Corporation and bluebird bio Announce Results from Ongoing Multicenter Phase 1 Study of bb2121 anti-BCMA CAR T Cell Therapy in Patients with Multiple Myeloma Published in New England Journal of Medicine
2019-05-01 08:00:00 | bluebird bio Appoints Joanne Smith-Farrell, Ph.D., to Chief Business Officer
2019-04-30 15:18:51 | 5 Biotech Stocks for a Long-Lived Portfolio
2019-04-30 09:15:01 | Small Gains Still Bring New Highs
2019-04-29 08:01:00 | 20 High-Growth Stocks For The Next 20 Years
2019-04-28 22:47:02 | Is a Beat in the Cards for Molina's MOH Earnings in Q1?
2019-04-27 07:33:00 | How a Medicare Rule Change Could Bring CAR-T Stocks Back to Life
2019-04-26 11:48:03 | Universal Health UHS Q1 Earnings, Revenues Miss Estimates
2019-04-26 11:42:03 | What's in Store for HCA Healthcare's HCA Q1 Earnings?
2019-04-26 11:38:03 | Is a Beat in Store for WellCare Health's WCG Q1 Earnings?
2019-04-25 14:20:03 | Why bluebird bio, Inc.'s NASDAQ:BLUE CEO Pay Matters To You
2019-04-25 11:55:03 | Tenet Healthcare THC to Post Q1 Earnings: What's in Store?
2019-04-24 11:25:03 | Anthem's ANTM Q1 Earnings Beat Estimates, Improve Y/Y
2019-04-24 10:33:02 | Bluebird Bio BLUE Expected to Beat Earnings Estimates: Should You Buy?
2019-04-24 05:46:31 | Ahead of 1st drug approval, bluebird CEO's pay triples to $24M
2019-04-23 18:20:00 | SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Breaches of Fiduciary Duty by the Certain Officers and Directors of bluebird bio, Inc.
2019-04-22 15:09:07 | Did Hedge Funds Drop The Ball On bluebird bio Inc BLUE ?
2019-04-22 13:54:15 | This Is Why You Shouldn’t Count Regeneron Stock Out
2019-04-19 14:48:00 | Top Gene-Sequencing Stocks for 2019
2019-04-18 14:45:40 | Cambridge's bluebird bio expanding Kendall Square HQ
2019-04-17 17:15:15 | Here's Why Shares of bluebird bio Slumped Today
2019-04-15 14:00:15 | Four Companies Could Power The New Genomics ETF
2019-04-09 10:52:00 | Why bluebird bio Could Deliver Miracles to Genetic Disease Patients
2019-04-09 10:50:22 | See what the IHS Markit Score report has to say about bluebird bio Inc.
2019-04-09 09:53:00 | 5 Stocks in the Age of Miracles
2019-04-08 18:11:10 | Celgene & Acceleron Submit BLA for Luspatercept to the FDA
2019-04-07 09:05:00 | 3 High-Growth Genomics Stocks You Can Buy
2019-03-31 11:01:00 | 2 Blockbuster Gene Therapy Programs to Watch in 2019
2019-03-29 09:33:12 | Most Analysts Have Given bluebird bio Positive Ratings in March
2019-03-29 07:47:42 | EMA panel recommends approval of Bluebird Bio's first gene therapy
2019-03-29 07:44:00 | bluebird bio Receives Positive Opinion from CHMP for ZYNTEGLO™ autologous CD34+ cells encoding ?A-T87Q-globin gene Gene Therapy for Patients 12 Years and Older with Transfusion-Dependent ?-Thalassemia TDT Who Do Not Have ?0/?0 Genotype
2019-03-26 17:15:09 | Celgene CELG Submits NDA for MS Drug to FDA for Review
2019-03-26 08:55:56 | See what the IHS Markit Score report has to say about bluebird bio Inc.
2019-03-25 08:24:04 | Massachusetts concern details plan to hire new workers in Durham
2019-03-23 09:30:01 | Why Is Bluebird BLUE Up 15.3% Since Last Earnings Report?
2019-03-12 10:30:05 | See what the IHS Markit Score report has to say about bluebird bio Inc.